IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸外科
学科主题临床医学
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma
Lv, Chao1; Ma, Yuanyuan1; Feng, Qin2; Fang, Fang1; Bai, Hua3; Zhao, Bingtian1; Yan, Shi1; Wu, Nan1; Zheng, Qingfeng1; Li, Shaolei1; Chen, Jinfeng1; Wang, Jia1; Feng, Yuan1; Wang, Yuzhao1; Pei, Yuquan1; Fang, Jian4; Yang, Yue1
关键词Non-small-cell Lung Cancer Sequential Induction Chemotherapy Egfr Mutation Adenocarcinoma
刊名WORLD JOURNAL OF SURGICAL ONCOLOGY
2013-04-26
DOI10.1186/1477-7819-11-96
11
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Surgery
研究领域[WOS]Oncology ; Surgery
关键词[WOS]TYROSINE KINASE INHIBITOR ; FACTOR RECEPTOR MUTATIONS ; PHASE-III ; EGFR MUTATIONS ; CANCER ; GEFITINIB ; CISPLATIN ; TRIAL ; CARBOPLATIN ; COMBINATION
英文摘要

Background: A phase II clinical trial previously evaluated the sequential administration of erlotinib after chemotherapy for advanced non-small-cell lung cancer (NSCLC). This current pilot study assessed the feasibility of sequential induction therapy in patients with stage IIB to IIIA NSCLC adenocarcinoma.

Methods: Patients received gemcitabine 1,250 mg/m(2) on days 1 and 8 and cisplatin 75 mg/m(2) on day 1, followed by oral icotinib (125 mg, three times a day) on days 15 to 28. A repeatcomputed tomography(CT) scan evaluated the response to the induction treatment after two 4-week cycles and eligible patients underwent surgical resection. The primary objective was to assess the objective response rate (ORR), while EGFR and KRAS mutations and mRNA and protein expression levels of ERCC1 and RRM1 were analyzed in tumor tissues and blood samples.

Results: Eleven patients, most with stage IIIA disease, completed preoperative treatment. Five patients achieved partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (ORR=45%) and six patients underwent resection. Common toxicities included neutropenia, alanine transaminase (ALT) elevation, fatigue, dry skin, rash, nausea, alopecia and anorexia. No serious complications were recorded perioperatively. Three patients had exon 19 deletions and those with EGFR mutations were more likely to achieve a clinical response (P=0.083). Furthermore, most cases who achieved a clinical response had low levels of ERCC1 expression and high levels of RRM1.

Conclusions: Two cycles of sequentially administered gemcitabine/cisplatin with icotinib as an induction treatment is a feasible and efficacious approach for stage IIB to IIIA NSCLC adenocarcinoma, which provides evidence for the further investigation of these chemotherapeutic and molecularly targeted therapies.

语种英语
WOS记录号WOS:000318495600001
资助机构Zhejiang Beta Pharma Inc.
引用统计
被引频次:17[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50185
专题北京大学临床肿瘤学院_胸外科
北京大学临床肿瘤学院_胸部肿瘤外二科
北京大学临床肿瘤学院_日间化疗病区
北京大学临床肿瘤学院_病理科
作者单位1.Peking Univ, Canc Hosp & Inst, Dept Pathol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Canc Hosp & Inst, Dept Thorac Surg 2, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
3.Peking Univ, Canc Hosp & Inst, Dept Thorac Med Oncol 1, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
4.Peking Univ, Canc Hosp & Inst, Dept Thorac Med Oncol 2, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Lv, Chao,Ma, Yuanyuan,Feng, Qin,et al. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma[J]. WORLD JOURNAL OF SURGICAL ONCOLOGY,2013,11.
APA Lv, Chao.,Ma, Yuanyuan.,Feng, Qin.,Fang, Fang.,Bai, Hua.,...&Yang, Yue.(2013).A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.WORLD JOURNAL OF SURGICAL ONCOLOGY,11.
MLA Lv, Chao,et al."A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma".WORLD JOURNAL OF SURGICAL ONCOLOGY 11(2013).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lv, Chao]的文章
[Ma, Yuanyuan]的文章
[Feng, Qin]的文章
百度学术
百度学术中相似的文章
[Lv, Chao]的文章
[Ma, Yuanyuan]的文章
[Feng, Qin]的文章
必应学术
必应学术中相似的文章
[Lv, Chao]的文章
[Ma, Yuanyuan]的文章
[Feng, Qin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。